Sign in
Not yet recruitingPhase 3

Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)

Key facts

Who runs it
Mahidol University
Where
Thailand1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
304 people, planned
Started
1 Dec 2025
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Human Albumin 20% Solution
  • Standard Care (in control arm)
Record updated
19 November 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Adult patients (≥18 years) admitted to the surgical intensive care unit (SICU)
  • Diagnosis or suspicion of surgical infection requiring surgery or surgical intervention within 48 hours of ICU admission
  • Septic shock, defined as:
  • Mean arterial pressure <65 mmHg after adequate fluid resuscitation or requirement for vasopressors to maintain mean arterial pressure (MAP) ≥65 mmHg for at least 1 hour, and
  • Evidence of organ dysfunction (Sequential Organ Failure Assessment (SOFA) score increase ≥2) or signs of tissue hypoperfusion (serum lactate >2 mmol/L, oliguria <0.5 mL/kg/h >2 h, or clinical evidence of poor peripheral perfusion)

Who cannot take part

  • End-stage renal disease or receiving chronic renal replacement therapy
  • Contraindication to albumin infusion or history of severe allergic reaction to albumin
  • Conditions where albumin infusion is already indicated (e.g., large-volume paracentesis >5 L, hepatorenal syndrome, spontaneous bacterial peritonitis, plasmapheresis, cirrhosis, nephrotic syndrome, protein-losing enteropathy, severe burns, post-cardiac or thoracic surgery)
  • Refusal of consent or do-not-resuscitate (DNR) status
  • More than 24 hours since meeting inclusion criteria
  • Evidence of fluid overload or pulmonary edema (bilateral crepitations, chest infiltrates consistent with pulmonary edema, Central Venous Pressure >15 mmHg, Pulmonary Artery Occlusion Pressure [PAOP] >18 mmHg, or N-terminal pro-B-type Natriuretic Peptide [NT-proBNP] >900 pg/mL)
  • Pregnancy or breastfeeding

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Critical illness or septic shock

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will test whether giving human albumin to keep the blood albumin level above 3.5 g/dL, in addition to standard care, improves survival in patients with surgical septic shock. Septic shock is a life-threatening complication of infection that often requires urgent surgery and intensive care. Current treatment guidelines recommend intravenous fluids and medications to support blood pressure, but the best type of fluid is still uncertain.

Read full original descriptionShow less

Human albumin is a natural protein in the blood that helps maintain fluid balance and has anti-inflammatory effects. Previous studies suggest that low albumin levels are linked with worse outcomes in septic patients, and that albumin infusion might improve recovery, but results are mixed and evidence in surgical septic shock patients is lacking.

In this randomized controlled trial, adult patients with surgical septic shock admitted to the surgical intensive care unit will be randomly assigned to receive either standard care alone or standard care plus 20% human albumin solution for up to 3 days. The main outcome is survival at 28 days. Secondary outcomes include length of ICU and hospital stay, need for dialysis, ventilator-free days, vasopressor-free days, fluid balance, gastrointestinal recovery, and adverse reactions.

The results of this study will help determine whether targeted albumin replacement is beneficial in critically ill surgical patients with septic shock and could guide future fluid resuscitation strategies.

The 2 groups in the trial

  • Standard CareExisting treatment, for comparison

    Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.

    Treatment: Standard Care (in control arm)

  • Standard Care Plus AlbuminTreatment being tested

    Patients in this group will receive standard sepsis management as above, plus intravenous 20% human albumin solution. On admission, 50 mL of 20% albumin will be infused over 2 hours, followed by additional doses for up to 72 hours, titrated according to daily serum albumin levels. The target is to maintain serum albumin \>3.5 g/dL: 1 vial every 12 hours if 2.5-3.4 g/dL, or every 6 hours if \<2.5 g/dL. Infusion will be withheld in the presence of fluid overload, pulmonary edema, or severe hypernatremia.

    Treatment: Human Albumin 20% Solution and Standard Care (in control arm)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study of the Additional Human Albumin During Resuscitation in Patients With Surgical Septic Shock in Surgical Intensive Care Units: A Randomized Controlled Trial (The ALBumin Use in Surgical Septic Shock, ALBUS Study)
Criteria questions
Built from NCT07212582, who can take part
Record updated
19 November 2025